and the 11 Chiron Corporation, Emeryville, California 94608 Sporozoites are the infective stage of malaria parasites present in the salivary glands of Anopheles mosquitoes . An effective vaccine against sporozoites should prevent infection and, together with the use of residual insecticides and chemoprophylactic agents, contribute to the control of the disease. Sporozoite vaccines against Plasmodium falciparum, containing part or the entire repeat domain of the circumsporozoite (CS) protein, have recently undergone their first clinical trials in human volunteers (1, 2). The choice of this antigen was based mainly on studies showing that in vitro incubation of sporozoites with mAb to the repeated subunit sequences of CS proteins abolished their infectivity. Moreover, passive transfer of the mAb to the mammalian hosts before the inoculation of sporozoites protected them from malaria infection (reviewed in reference 3).Left unanswered are important questions regarding the effectiveness of vaccines containing CS protein repeats, and the role of antibody and T cell effector mechanisms in protection . These questions could only recently be approached experimentally, when the CS gene of Plasmodium berghei, a rodent malaria parasite, was cloned and the corresponding amino acid sequence was elucidated (4). This sequence contains a central region with tandemly repeated amino acid units, varying somewhat in composition, DPPPPNP PN' In competitive binding assays the (DPPPPNPN) 2D peptide was 30-50 times better at inhibiting the interaction of an mAb (3D11) with P. berghei sporozoites than the alternative form, the (DPAPPNAN)2D peptide (4). Because the mAb 3D11 neutralizes the infectivity of sporozoites very effectively (5), we postulated that vaccination of mice with synthetic peptides containing the (DPPPPNPN)2D sequence might induce protective antibodies when coupled with an appropriate carrier. The present experiments address this question in a rodent model.
Materials and MethodsSynthesis ofPeptides 17.1 and 17 .2. A 17-mer peptide of the tandemly repeating domain of P. berghei (DPPPPNPN)2, designated 17